证券之星消息，11月19日中药板块较上一交易日下跌1.28%，嘉应制药领跌。当日上证指数报收于 3946.74，上涨0.18%。深证成指报收于13080.09，下跌0.0%。中药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 300391 | *ST长药 | 2.36 | 6.79% | 57.94万 | 1.32亿 | | 000538 | 云南白药 | 56.40 | 0.02% | 5.61万 | 3.16亿 | | 300181 | 佐力药业 | 17.30 | -0.17% | 4.21万 | 7276.54万 | | 000423 | 东阿阿胶 | 48.31 | -0.21% | 3.02万 | 1.46亿 | | 600750 | 江中药业 | 21.94 | -0.27% | 4.99万 | 1.10亿 | | 600436 | 片仔瘦 | 176.21 | -0.39% | 1.12万 | 1.97亿 | | 600285 | 羚锐制药 | 22.16 ...

■ 江中药业股份有限公司 关于变更审计项目合伙人、签字注册会计师及 质量控制复核人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 新任项目合伙人、签字注册会计师孙文举先生，2009年取得中国注册会计师资格，2001年开始在毕马威 华振执业，2001年开始从事上市公司审计，从2025年开始为公司提供服务。孙文举先生近三年签署或复 核上市公司审计报告1份。 新任签字注册会计师王习文先生，2013年取得中国注册会计师资格。王习文先生2023年起开始在毕马威 华振执业，2015年开始从事上市公司审计，从2025年开始为公司提供审计服务，王习文先生近三年未签 署或复核上市公司审计报告。 新任质量控制复核人陈怡女士，2011年取得中国注册会计师资格，2001年开始在毕马威华振执业，2002 年开始从事上市公司审计，从2025年开始为公司提供审计服务。陈怡女士近三年签署或复核上市公司审 计报告4份。 2、诚信记录 本项目合伙人、签字注册会计师孙文举先生、签字注册会计师王习文先生与质量控制复核人陈怡女士最 近三年均未因执业行为受 ...

证券代码：600750 证券简称：江中药业 公告编号：2025-058 江中药业股份有限公司 关于变更审计项目合伙人、签字注册会计师及质量控制 复核人的公告 新任质量控制复核人陈怡女士，2011 年取得中国注册会计师资格，2001 年开始 在毕马威华振执业，2002 年开始从事上市公司审计，从 2025 年开始为公司提供审计 服务。陈怡女士近三年签署或复核上市公司审计报告 4 份。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 江中药业股份有限公司（以下简称"公司"）于 2025 年 8 月 20 日召开第十届董 事会第七次会议和第十届监事会第七次会议，并于 2025 年 9 月 8 日召开 2025 年第一 次临时股东大会，审议通过了《关于续聘 2025 年度审计机构的议案》，同意续聘毕马 威华振会计师事务所（特殊普通合伙）（以下简称"毕马威华振"）为公司 2025 年度 审计机构，负责本公司年度财务报告审计、内部控制审计及相关专项审计工作（以下 简称"本项目"），聘用期为一年。具体内容详见公司于 2025 年 8 ...

科技创新浪潮澎湃，赣鄱大地产业焕新。 上百个机械臂此起彼落，无人驾驶AGV小车搬运穿梭……走进江中药谷智能化生产车间，满满的科技 感扑面而来。"从取材到预处理、提取、灌装、灭菌直至包装、成箱、入库，生产线整个操作流程均实 现自动化无人操作。"华润江中湾里制造基地负责人钟志坚介绍，液体制剂车间只需10余人就能完成操 作管理，而同等产量的传统车间需要近200人，智能化让生产效率大幅提升。 制造企业向产业链价值链高端攀升，前景远阔。从最初生产橡胶筛网、渣浆泵备件，到如今参与矿产资 源开发，构建"设备 + 资源"双轮驱动模式，耐普矿机不再满足于"卖配件"，而是从"全球耗材供应 商"向"矿业综合服务商"转型，持续拓展传统矿业设备企业的价值边界。 一片薄薄的中空纤维血液透析膜，曾是制约国内血液净化产业发展的 "卡脖子"难题。如今，这条由三 鑫医疗自主研发的国产透析膜生产线，让"民族品牌"在血液净化领域站稳脚跟。从1997年生产输液器的 小厂，到如今血液净化产品营收占比超 80%的行业标杆，三鑫医疗营收10年增4倍的转型轨迹，印刻着 江西医疗器械产业提质升级的突围之路。 走出福事特上饶生产车间时，夕阳正洒在"FIRST"的 ...

Core Insights - Jiangzhong Pharmaceutical has established itself as a leader in the traditional Chinese medicine (TCM) sector, particularly with its flagship product, Jiangzhong Gastrointestinal Tablets, which has achieved over 10 billion yuan in annual sales and has sold more than 5 billion boxes over 30 years [1][5]. Group 1: Business Performance - Jiangzhong Gastrointestinal Tablets has maintained its position as the top-selling TCM digestive product in China for 21 consecutive years, reflecting strong brand loyalty and market presence [1]. - The company has reported a compound annual growth rate (CAGR) of 16% in revenue and 13% in net profit during the 14th Five-Year Plan period [1]. Group 2: Technological Innovation - The Jiangzhong Bay manufacturing base features an intelligent production line that automates the entire process from raw material handling to packaging, significantly reducing labor requirements from 200 to just over 10 personnel in liquid formulation [2][3]. - The company has achieved over 95% automation in its TCM extraction and production processes, marking a significant shift from traditional methods to smart manufacturing [3]. Group 3: Product Development - Jiangzhong Pharmaceutical has innovated traditional formulas, such as the "Shengmai San," by integrating modern ingredients to create products like "Huangqi Shengmai Drink," enhancing their appeal and efficacy [4]. - The company has focused on improving the taste and palatability of its products, such as the Jiangzhong Gastrointestinal Tablets, through advanced flavor masking and purification techniques [5]. Group 4: Cultural Integration - The company has launched initiatives like the "Jiangzhong Night Consumption Season," which creatively combines TCM ingredients with popular food trends, such as a digestive hot pot that incorporates elements from Jiangzhong Gastrointestinal Tablets [6]. - Jiangzhong Pharmaceutical aims to enhance the public's understanding and appreciation of TCM through cultural exhibitions and immersive experiences, thereby promoting the integration of traditional medicine into modern lifestyles [7].

Group 1: Jiangzhong Pharmaceutical - Jiangzhong Pharmaceutical's flagship product, Jianwei Digestive Tablets, has achieved cumulative sales of over 5 billion boxes and has been the top-selling OTC digestive medicine in China for 21 consecutive years [20][21] - The company aims to enhance quality through innovation, focusing on three main business areas: OTC products, health consumer goods, and prescription drugs, achieving a compound annual growth rate (CAGR) of 16% in revenue and 13% in net profit during the 14th Five-Year Plan period [20][21] - The company has implemented smart manufacturing technologies, achieving over 95% automation in its production processes, significantly improving efficiency and reducing labor costs [22][23] Group 2: Technological Innovation - Jiangzhong Pharmaceutical has developed a unique MVR concentration technology that enhances the extraction efficiency of active ingredients from traditional Chinese medicine to over 90% [22] - The company has established a national key laboratory for modern Chinese medicine creation, focusing on the innovative transformation of classic formulas into modern products [24] - The introduction of innovative flavors and purification techniques has transformed traditional herbal medicines into more palatable products, appealing to a broader consumer base [25] Group 3: Cultural Integration and Market Expansion - Jiangzhong Pharmaceutical has launched a "Healthy Hot Pot" concept that incorporates traditional medicinal ingredients, aiming to modernize and popularize traditional Chinese medicine among younger consumers [26][27] - The company plans to continue expanding its cultural outreach and application of traditional Chinese medicine through various channels, including tourism and dining [27] Group 4: Fushite Company - Fushite has positioned itself in the hydraulic pipeline sector, with a strategic focus on the mining after-market, anticipating a market size of $19.33 billion by 2030 [28][30] - The company has established a comprehensive service system that includes industrial maintenance and heavy spare parts supply, expanding its service capabilities beyond just hydraulic pipeline repairs [32] Group 5: Naipu Mining Machinery - Naipu Mining Machinery has developed a global service network covering over 50 countries, focusing on wear-resistant materials and mining machinery [34][36] - The company has successfully transitioned from basic spare parts production to advanced wear-resistant materials, leveraging new material technologies to enhance product performance [35][36] - Naipu's international strategy includes establishing production bases in Peru to meet the growing demand for mining equipment and spare parts in South America [39][40] Group 6: Sanxin Medical - Sanxin Medical has transformed from a traditional infusion and injection company to a significant player in the blood purification medical device sector, achieving a CAGR of 29.82% in net profit over the past five years [42][45] - The company has expanded its product offerings in blood purification, with revenue from this segment increasing from 20% in 2015 to 81% in 2024 [45] - Sanxin Medical is actively pursuing global market expansion, with overseas revenue growing by 39.70% in 2024, indicating a strong international presence [48][49]

| 序号 | 代码 | 简称 | 車日涨幅 | 年内涨幅 | 股息率(近12个 | | --- | --- | --- | --- | --- | --- | | | | | (%) | (%) | 月) (%) | | 1 | 002083.SZ | 录日股份 | 9.99 | 143.49 | 1.37 | | 2 | 600211.SH | 西藏药业 | 1.86 | 35.24 | 3.99 | | 3 | 601686.SH | 友发集团 | 1.82 | 29.54 | 4.38 | | 4 | 603408.SH | 建霖家居 | 1.73 | 7.82 | 5.74 | | 5 | 601988.SH | 中国银行 | 1.39 | 10.34 | 3.86 | | 6 | 688516.SH | 奥特维 | 1.14 | 10.60 | 4.70 | | 7 | 600351 SH | 亚宝药业 | 1.00 | 21.34 | 4.30 | | 8 | 002895.SZ | 川恒股份 | 1.00 | 66.43 | 3.63 | | a | 603967.SH | 中创物流 | 0.9 ...

Summary of Conference Call Records Industry Overview - The pharmaceutical and healthcare sectors are currently experiencing a shift, with companies like沃伍生物, 方盛制药, and 佐力药业 showing strong stock performance and potential investment opportunities due to their solid revenue, profit, and cash flow [1][3] - The medical services industry is facing challenges due to DRG policies and a weak consumer environment, but improvements are expected by 2026 as supply-side constraints and potential mergers or new hospital openings may enhance performance metrics [1][4] Key Companies and Investment Opportunities - **Ophthalmology Sector**: Companies such as 爱尔, 华夏, and 普瑞 are recommended for investment, with expectations of performance release in refractive services by Q1 2026 and improvements in cataract screening next year [1][5] - **Dental Sector**: 通策医疗 is highlighted for its new hospital openings and expected revenue and profit growth in 2026, indicating a turning point for the company [1][6] - **Pharmaceutical Companies**: 流感-related companies like 国邦, 普洛药业, and 联邦制药 are experiencing high capacity utilization and are expected to see significant growth in Q4 and Q1 due to potential shortages and price increases [2][12] Market Trends and Predictions - The blood products industry is consolidating, with a focus on mergers and acquisitions, which may stabilize product prices and enhance demand in the context of flu outbreaks [8] - The vaccine industry is poised for growth with key players like 康华生物 and 康希诺 expected to release significant data and products in 2026, which could drive market interest [9][10] - The traditional Chinese medicine sector is forecasted to recover, with a focus on innovative drug companies and OTC brands that are well-positioned for growth [13] Retail Pharmacy Sector - The retail pharmacy sector is expected to benefit from consolidation as smaller chains face operational pressures, allowing leading companies like 益丰, 大森林, and 老百姓 to capitalize on improved consumer conditions and policy support [14] Conclusion - The overall sentiment in the pharmaceutical and healthcare sectors is cautiously optimistic, with several companies positioned for growth amid a backdrop of regulatory changes and market dynamics. Investors are encouraged to focus on companies with strong fundamentals and growth potential in the coming years [1][3][4][12][14]

Core Insights - Recently, the establishment of China Resources (Chengdu) Pharmaceutical Industry Equity Investment Fund Partnership (Limited Partnership) was announced, with a total investment of 1 billion RMB, focusing on venture capital in the pharmaceutical sector [1] Group 1: Fund Establishment - The fund is executed by China Resources Pharmaceutical Technology (Chengdu) Partnership (Limited Partnership) and has a registered capital of 1 billion RMB [1] - The fund's partners include Chengdu Major Industrialization Project Phase II Equity Investment Fund Co., Ltd., Boya Bio (300294), Dong-E E-Jiao (000423), China Resources Double Crane (600062), and Jiangzhong Pharmaceutical (600750) [1] Group 2: Investment Focus - In July, several listed companies under China Resources announced plans to jointly invest in the establishment of China Resources Pharmaceutical (Chengdu) Innovation Investment Fund Partnership (Limited Partnership) [1] - This new fund will focus on the main responsibilities of the pharmaceutical health sector and strategic emerging industries [1]

Core Insights - Recently, China Resources (Chengdu) Pharmaceutical Industry Equity Investment Fund Partnership (Limited Partnership) was established with a capital contribution of 1 billion yuan [1] - The fund's business scope includes venture capital, specifically limited to investments in unlisted companies [1] - The fund is jointly funded by several companies, including Fosun Pharma, Dong-E E-Jiao, Boya Bio, China Resources Double Crane, and Jiangzhong Pharmaceutical [1] Company Contributions - Fosun Pharma's wholly-owned subsidiary, Shanghai Fosun Pharmaceutical Industry Development Co., Ltd., is a key contributor to the fund [1] - Other contributors include Dong-E E-Jiao, Boya Bio, China Resources Double Crane, and Jiangzhong Pharmaceutical, indicating a collaborative investment approach among major players in the pharmaceutical industry [1] Investment Focus - The fund is specifically focused on venture investments, which suggests a strategic interest in supporting early-stage pharmaceutical companies [1] - The emphasis on unlisted companies may provide opportunities for high-growth potential investments within the pharmaceutical sector [1]